Wunderlich, M; Manning, N; Sexton, C; O’Brien, E; Byerly, L; Stillwell, C; Perentesis, JP; Mulloy, JC; Mizukawa, B. PD-1 Inhibition Enhances Blinatumomab Response in a UCB/PDX Model of Relapsed Pediatric B-Cell Acute Lymphoblastic Leukemia. Frontiers in Oncology. 2021; 11:642466.

Su, R; Dong, L; Li, Y; Gao, M; Han, L; Wunderlich, M; Deng, X; Li, H; Huang, Y; Gao, L; Mulloy, JC; Wei, M; Horne, D; Chen, J. Targeting FTO Suppresses Cancer Stem Cell Maintenance and Immune Evasion. Cancer Cell. 2020; 38:79-96.e11.

Rodriguez, S; Abundis, C; Boccalatte, F; Mehrotra, P; Chiang, MY; Yui, MA; Wang, L; Zhang, H; Zollman, A; Bonfim-Silva, R; Marcucci, G; Aifantis, I; Cardoso, AA; Carlesso, N. Therapeutic targeting of the E3 ubiquitin ligase SKP2 in T-ALL. Leukemia. 2020; 34:1241-1252.

Hinge, A; He, J; Bartram, J; Javier, J; Xu, J; Fjellman, E; Sesaki, H; Li, T; Yu, J; Wunderlich, M; Mulloy, J; Kofron, M; Salomonis, N; Grimes, HL; Filippi, M. Asymmetrically Segregated Mitochondria Provide Cellular Memory of Hematopoietic Stem Cell Replicative History and Drive HSC Attrition. Cell Stem Cell. 2020; 26:420-430.e6.

Khodoun, MV; Morris, SC; Angerman, E; Potter, C; Schuman, R; Wunderlich, M; Maciag, JJ; Locker, KC S; Mulloy, JC; Herr, AB; Finkelman, FD. Rapid desensitization of humanized mice with anti-human FcεRIα monoclonal antibodies. Journal of Allergy and Clinical Immunology. 2020; 145:907-921.e3.

Wunderlich, M; Manning, N; Sexton, C; Sabulski, A; Byerly, L; O'Brien, E; Perentesis, JP; Mizukawa, B; Mulloy, JC. Improved chemotherapy modeling with RAG-based immune deficient mice. PloS one. 2019; 14:e0225532.

Melgar, KM; Jones, LM; Walker, M; Bolanos, LC; Hueneman, K; Wunderlich, M; Jiang, J; Wilson, K; Zhang, X; Sutter, P; Rosenbaum, JS; Perentesis, JP; Thomas, CJ; Starczynowski, DT. Overcoming Adaptive Therapy Resistance in AML By Targeting Immune Response Pathways. Blood. 2019; 134:3934.

Wunderlich, M; Chen, J; O'Brien, E; Manning, N; Sexton, C; Byerly, L; Perentesis, JP; Mizukawa, B; Mulloy, JC. Global Gene Expression and Mutation Signatures Are Preserved in PDX Models of Pediatric AML and Aid Discovery of Targeted Therapy for Cases with CBFA2T3/GLIS2 Rearrangement. Blood. 2019; 134:3766.

Melgar, K; Walker, MM; Jones, LM; Bolanos, LC; Hueneman, K; Wunderlich, M; Jiang, J; Wilson, KM; Zhang, X; Sutter, P; Levine, RL; Perentesis, JP; Thomas, CJ; Starczynowski, DT. Overcoming adaptive therapy resistance in AML by targeting immune response pathways. Science Translational Medicine. 2019; 11.

Tirtakusuma, R; Milne, P; Ptasinska, A; Meyer, C; Nakjang, S; Komkov, A; Williamson, D; Cauchy, P; Assi, S; Blair, H; Allan, JM; Bonifer, C; Heidenreich, O; Bomken, S. Epigenetic Regulator Genes Direct the Fate of Multipotent Progenitor Cell of Origin in Lineage Switched MLL-AF4 Leukaemia. 2019.

Li, Y; Xue, M; Deng, X; Dong, L; Nguyen, LX T; Ren, L; Han, L; Li, C; Xue, J; Zhao, Z; Tian, J; Shen, B; Su, R; Chen, J. TET2-mediated mRNA demethylation regulates leukemia stem cell homing and self-renewal. Cell Stem Cell. 2023; 30:1072-1090.e10.

Bouffi, C; Wikenheiser-Brokamp, KA; Chaturvedi, P; Sundaram, N; Goddard, GR; Wunderlich, M; Brown, NE; Staab, JF; Latanich, R; Zachos, NC; Mulloy, JC; Zorn, AM; Wells, JM; Helmrath, MA. In vivo development of immune tissue in human intestinal organoids transplanted into humanized mice. Nature Biotechnology. 2023; 41:824-831.

Liu, X; Sato, N; Yabushita, T; Li, J; Jia, Y; Tamura, M; Asada, S; Fujino, T; Fukushima, T; Yonezawa, T; Shibata, T; Miyake, K; Kitamura, T; Goyama, S. IMPDH inhibition activates TLR-VCAM1 pathway and suppresses the development of MLL-fusion leukemia. EMBO Molecular Medicine. 2023; 15:e15631.

Han, L; Dong, L; Leung, K; Zhao, Z; Li, Y; Gao, L; Chen, Z; Xue, J; Qing, Y; Li, W; Wei, M; Su, R; Chen, J; Deng, X. METTL16 drives leukemogenesis and leukemia stem cell self-renewal by reprogramming BCAA metabolism. Cell Stem Cell. 2023; 30:52-68.e13.

Weng, H; Huang, F; Yu, Z; Chen, Z; Prince, E; Kang, Y; Zhou, K; Li, W; Hu, J; Fu, C; Horne, D; Wei, M; Huang, H; Chen, J. The m6A reader IGF2BP2 regulates glutamine metabolism and represents a therapeutic target in acute myeloid leukemia. Cancer Cell. 2022; 40:1566-1582.e10.

Li, Y; Deng, X; Dong, L; Han, L; Nguyen, LX T; Xue, J; Zhao, Z; Li, W; Qing, Y; Shen, C; Li, Z; Wei, M; Su, R; Chen, J. TET2-Mediated mRNA and DNA Oxidation in Leukemia Homing and Immune Evasion. Blood. 2022; 140:2975-2977.

Tirtakusuma, R; Szoltysek, K; Milne, P; Grinev, VV; Ptasinska, A; Chin, PS; Meyer, C; Nakjang, S; Hehir-Kwa, JY; Williamson, D; Allan, JM; Bonifer, C; Heidenreich, O; Bomken, S. Epigenetic regulator genes direct lineage switching in MLL/AF4 leukemia. Blood. 2022; 140:1875-1890.

Barreyro, L; Sampson, AM; Ishikawa, C; Hueneman, KM; Choi, K; Pujato, MA; Chutipongtanate, S; Wyder, M; Haffey, WD; O'Brien, E; Greis, KD; Nurmemmedov, E; Seibel, WL; Starczynowski, DT. Blocking UBE2N abrogates oncogenic immune signaling in acute myeloid leukemia. Science Translational Medicine. 2022; 14:eabb7695.

Wunderlich, M; Chen, J; Sexton, C; Manning, N; Byerly, L; O’Brien, E; Perentesis, J; Mulloy, J; Mizukawa, B. PDX models of relapsed pediatric AML preserve global gene expression patterns and reveal therapeutic targets. 2022; 2022.01.31.478534.

Zhao, H; Lu, J; Yan, T; Han, F; Sun, J; Yin, X; Chen, L; Shen, C; Wunderlich, M; Yun, W; Li, C; Chen, J; Huang, H; Jiang, X. Opioid receptor signaling suppresses leukemia through both catalytic and non-catalytic functions of TET2. Cell Reports. 2022; 38:110253.

Fishman, H; Madiwale, S; Geron, I; Bari, V; Van Loocke, W; Kirschenbaum, Y; Ganmore, I; Kugler, E; Rein-Gil, A; Friedlander, G; Nagler, A; Mulloy, JC; Van Vlierberghe, P; Izraeli, S. ETV6-NCOA2 fusion induces T/myeloid mixed-phenotype leukemia through transformation of nonthymic hematopoietic progenitor cells. Blood. 2022; 139:399-412.

Earnest, KG; McConnell, EM; Hassan, EM; Wunderlich, M; Hosseinpour, B; Bono, BS; Chee, MJ; Mulloy, JC; Willmore, WG; DeRosa, MC; Merino, EJ. Development and characterization of a DNA aptamer for MLL-AF9 expressing acute myeloid leukemia cells using whole cell-SELEX. Scientific Reports. 2021; 11:19174.

Wunderlich, M; Manning, N; Sexton, C; O’Brien, E; Byerly, L; Stillwell, C; Perentesis, JP; Mulloy, JC; Mizukawa, B. PD-1 Inhibition Enhances Blinatumomab Response in a UCB/PDX Model of Relapsed Pediatric B-Cell Acute Lymphoblastic Leukemia. Frontiers in Oncology. 2021; 11:642466.

Wunderlich, M; Manning, N; O'Brien, E; Sexton, C; Byerly, L; Perentesis, JP; Mizukawa, B; Mulloy, JC. Abstract 5412: Xenograft based detection of rare leukemic clones in minimal residual disease negative diagnostic specimens from pediatric patients. Cancer Research. 2020; 80:5412.

Su, R; Dong, L; Li, Y; Gao, M; Han, L; Wunderlich, M; Deng, X; Li, H; Huang, Y; Gao, L; Mulloy, JC; Wei, M; Horne, D; Chen, J. Targeting FTO Suppresses Cancer Stem Cell Maintenance and Immune Evasion. Cancer Cell. 2020; 38:79-96.e11.

Rodriguez, S; Abundis, C; Boccalatte, F; Mehrotra, P; Chiang, MY; Yui, MA; Wang, L; Zhang, H; Zollman, A; Bonfim-Silva, R; Marcucci, G; Aifantis, I; Cardoso, AA; Carlesso, N. Therapeutic targeting of the E3 ubiquitin ligase SKP2 in T-ALL. Leukemia. 2020; 34:1241-1252.

Khodoun, M; Peipp, M; Morris, SC; Angerman, E; Potter, C; Herr, A; Mulloy, J; Wunderlich, M; Finkelman, FD. Safe, rapid suppression of IgE-mediated allergy with monovalent (mv) anti-human (hu) FceRIa monoclonal antibody (mAb). Journal of immunology (Baltimore, Md. : 1950). 2020; 204:66.22.

Hinge, A; He, J; Bartram, J; Javier, J; Xu, J; Fjellman, E; Sesaki, H; Li, T; Yu, J; Wunderlich, M; Mulloy, J; Kofron, M; Salomonis, N; Grimes, HL; Filippi, M. Asymmetrically Segregated Mitochondria Provide Cellular Memory of Hematopoietic Stem Cell Replicative History and Drive HSC Attrition. Cell Stem Cell. 2020; 26:420-430.e6.

Khodoun, MV; Morris, SC; Angerman, E; Potter, C; Schuman, R; Wunderlich, M; Maciag, JJ; Locker, KC S; Mulloy, JC; Herr, AB; Finkelman, FD. Rapid desensitization of humanized mice with anti-human FcεRIα monoclonal antibodies. Journal of Allergy and Clinical Immunology. 2020; 145:907-921.e3.

Wunderlich, M; Manning, N; Sexton, C; Sabulski, A; Byerly, L; O'Brien, E; Perentesis, JP; Mizukawa, B; Mulloy, JC. Improved chemotherapy modeling with RAG-based immune deficient mice. PloS one. 2019; 14:e0225532.

Melgar, KM; Jones, LM; Walker, M; Bolanos, LC; Hueneman, K; Wunderlich, M; Jiang, J; Wilson, K; Zhang, X; Sutter, P; Rosenbaum, JS; Perentesis, JP; Thomas, CJ; Starczynowski, DT. Overcoming Adaptive Therapy Resistance in AML By Targeting Immune Response Pathways. Blood. 2019; 134:3934.

Wunderlich, M; Chen, J; O'Brien, E; Manning, N; Sexton, C; Byerly, L; Perentesis, JP; Mizukawa, B; Mulloy, JC. Global Gene Expression and Mutation Signatures Are Preserved in PDX Models of Pediatric AML and Aid Discovery of Targeted Therapy for Cases with CBFA2T3/GLIS2 Rearrangement. Blood. 2019; 134:3766.

Melgar, K; Walker, MM; Jones, LM; Bolanos, LC; Hueneman, K; Wunderlich, M; Jiang, J; Wilson, KM; Zhang, X; Sutter, P; Levine, RL; Perentesis, JP; Thomas, CJ; Starczynowski, DT. Overcoming adaptive therapy resistance in AML by targeting immune response pathways. Science Translational Medicine. 2019; 11.

Tirtakusuma, R; Milne, P; Ptasinska, A; Meyer, C; Nakjang, S; Komkov, A; Williamson, D; Cauchy, P; Assi, S; Blair, H; Allan, JM; Bonifer, C; Heidenreich, O; Bomken, S. Epigenetic Regulator Genes Direct the Fate of Multipotent Progenitor Cell of Origin in Lineage Switched MLL-AF4 Leukaemia. 2019.